AOD-9604

Mechanism

AOD-9604 corresponds to the C-terminal fragment of human growth hormone (hGH 177-191) with an additional tyrosine residue at position 177. Research suggests it mimics the lipolytic action of hGH by stimulating beta-3 adrenergic receptors on adipocytes and enhancing fat oxidation, while lacking the IGF-1-stimulating and hyperglycemic effects of full-length growth hormone. In vitro and animal studies have shown it promotes lipolysis and inhibits lipogenesis in adipose tissue without affecting carbohydrate metabolism or promoting longitudinal bone growth.

What the literature has looked at

• Studies have investigated its lipolytic activity in adipose tissue models
• Research has examined fat oxidation pathways without IGF-1 elevation
• Studies have explored its effects on body composition parameters in preclinical models
• Studies have assessed cartilage repair and regenerative potential

Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.

Cited work

• Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3 AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.

  Research investigated AOD-9604-mediated lipolytic signaling in obese mice, observing modulation of adipose tissue metabolism without IGF-1 stimulation or hyperglycemia, with effects shown to be mediated via beta-3 adrenergic receptors.

• Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.

  Phase II evaluation examined the safety and tolerability profile of AOD-9604, observing a tolerability profile comparable to placebo.

Properties

molecular Formula

C₇₈H₁₂₃N₂₁O₂₃S₂

molar Mass

~1815 g/mol

cas Number

221231-10-3

type

Peptide